Medical - Healthcare Plans
Compare Stocks
5 / 10Stock Comparison
ELV vs DBVT vs UNH vs ALKS vs MCK
Revenue, margins, valuation, and 5-year total return — side by side.
Biotechnology
Medical - Healthcare Plans
Biotechnology
Medical - Distribution
ELV vs DBVT vs UNH vs ALKS vs MCK — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Medical - Healthcare Plans | Biotechnology | Medical - Healthcare Plans | Biotechnology | Medical - Distribution |
| Market Cap | $80.98B | $1712.35T | $335.60B | $5.90B | $92.15B |
| Revenue (TTM) | $200.41B | $0.00 | $449.71B | $1.56B | $403.43B |
| Net Income (TTM) | $5.24B | $-168M | $12.04B | $153M | $4.76B |
| Gross Margin | 23.2% | — | 18.8% | 65.4% | 3.6% |
| Operating Margin | 3.8% | — | 4.2% | 12.3% | 1.5% |
| Forward P/E | 13.9x | — | 20.2x | 24.8x | 19.3x |
| Total Debt | $33.23B | $22M | $78.39B | $70M | $7.39B |
| Cash & Equiv. | $9.49B | $194M | $24.36B | $1.12B | $5.69B |
ELV vs DBVT vs UNH vs ALKS vs MCK — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Elevance Health Inc. (ELV) | 100 | 126.8 | +26.8% |
| DBV Technologies S.… (DBVT) | 100 | 41.2 | -58.8% |
| UnitedHealth Group … (UNH) | 100 | 121.3 | +21.3% |
| Alkermes plc (ALKS) | 100 | 216.4 | +116.4% |
| McKesson Corporation (MCK) | 100 | 474.1 | +374.1% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ELV vs DBVT vs UNH vs ALKS vs MCK
Each card shows where this stock fits in a portfolio — not just who wins on paper.
ELV is the #2 pick in this set and the best alternative if sleep-well-at-night and defensive is your priority.
- Lower volatility, beta 0.46, Low D/E 75.5%, current ratio 1.24x
- Beta 0.46, yield 1.8%, current ratio 1.24x
- Lower P/E (13.9x vs 20.2x)
DBVT ranks third and is worth considering specifically for momentum.
- +110.4% vs ELV's -9.0%
UNH is the clearest fit if your priority is income & stability.
- Dividend streak 25 yrs, beta 0.59, yield 2.4%
- 2.4% yield, 25-year raise streak, vs ELV's 1.8%, (2 stocks pay no dividend)
ALKS is the clearest fit if your priority is quality.
- 9.8% margin vs DBVT's 0.3%
MCK carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- Rev growth 16.2%, EPS growth 14.9%, 3Y rev CAGR 10.8%
- 348.1% 10Y total return vs UNH's 220.6%
- PEG 0.49 vs ELV's 2.01
- 16.2% revenue growth vs DBVT's -100.0%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 16.2% revenue growth vs DBVT's -100.0% | |
| Value | Lower P/E (13.9x vs 20.2x) | |
| Quality / Margins | 9.8% margin vs DBVT's 0.3% | |
| Stability / Safety | Beta 0.04 vs DBVT's 1.26 | |
| Dividends | 2.4% yield, 25-year raise streak, vs ELV's 1.8%, (2 stocks pay no dividend) | |
| Momentum (1Y) | +110.4% vs ELV's -9.0% | |
| Efficiency (ROA) | 5.7% ROA vs DBVT's -89.0% |
ELV vs DBVT vs UNH vs ALKS vs MCK — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
ELV vs DBVT vs UNH vs ALKS vs MCK — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
MCK leads in 2 of 6 categories
ALKS leads 1 • UNH leads 1 • ELV leads 0 • DBVT leads 0 • 2 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
ALKS leads this category, winning 5 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
UNH and DBVT operate at a comparable scale, with $449.7B and $0 in trailing revenue. ALKS is the more profitable business, keeping 9.8% of every revenue dollar as net income compared to MCK's 1.2%. On growth, ALKS holds the edge at +28.2% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $200.4B | $0 | $449.7B | $1.6B | $403.4B |
| EBITDAEarnings before interest/tax | $8.9B | -$112M | $23.2B | $212M | $6.8B |
| Net IncomeAfter-tax profit | $5.2B | -$168M | $12.0B | $153M | $4.8B |
| Free Cash FlowCash after capex | $6.5B | -$151M | $19.7B | $392M | $6.0B |
| Gross MarginGross profit ÷ Revenue | +23.2% | — | +18.8% | +65.4% | +3.6% |
| Operating MarginEBIT ÷ Revenue | +3.8% | — | +4.2% | +12.3% | +1.5% |
| Net MarginNet income ÷ Revenue | +2.6% | — | +2.7% | +9.8% | +1.2% |
| FCF MarginFCF ÷ Revenue | +3.2% | — | +4.4% | +25.1% | +1.5% |
| Rev. Growth (YoY)Latest quarter vs prior year | +2.6% | — | +2.0% | +28.2% | +6.0% |
| EPS Growth (YoY)Latest quarter vs prior year | -16.8% | +91.5% | +0.7% | -4.1% | +37.0% |
Valuation Metrics
Evenly matched — ELV and DBVT and MCK each lead in 2 of 7 comparable metrics.
Valuation Metrics
At 14.8x trailing earnings, ELV trades at a 49% valuation discount to MCK's 29.2x P/E. Adjusting for growth (PEG ratio), MCK offers better value at 0.75x vs ELV's 2.15x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $81.0B | $1712.35T | $335.6B | $5.9B | $92.1B |
| Enterprise ValueMkt cap + debt − cash | $104.7B | $1712.35T | $389.6B | $4.9B | $93.8B |
| Trailing P/EPrice ÷ TTM EPS | 14.84x | -0.76x | 27.95x | 24.76x | 29.25x |
| Forward P/EPrice ÷ next-FY EPS est. | 13.93x | — | 20.19x | — | 19.28x |
| PEG RatioP/E ÷ EPS growth rate | 2.15x | — | — | — | 0.75x |
| EV / EBITDAEnterprise value multiple | 10.84x | — | 16.70x | 17.25x | 18.74x |
| Price / SalesMarket cap ÷ Revenue | 0.41x | — | 0.75x | 4.00x | 0.26x |
| Price / BookPrice ÷ Book value/share | 1.88x | 0.66x | 3.31x | 3.28x | — |
| Price / FCFMarket cap ÷ FCF | 25.51x | — | 20.88x | 12.28x | 17.63x |
Profitability & Efficiency
MCK leads this category, winning 5 of 9 comparable metrics.
Profitability & Efficiency
MCK delivers a 3.0% return on equity — every $100 of shareholder capital generates $3 in annual profit, vs $-130 for DBVT. ALKS carries lower financial leverage with a 0.04x debt-to-equity ratio, signaling a more conservative balance sheet compared to UNH's 0.77x. On the Piotroski fundamental quality scale (0–9), ALKS scores 7/9 vs DBVT's 4/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | +11.9% | -130.2% | +11.5% | +8.8% | +3.0% |
| ROA (TTM)Return on assets | +4.3% | -89.0% | +3.9% | +5.4% | +5.7% |
| ROICReturn on invested capital | +9.1% | — | +9.2% | +18.9% | +5.4% |
| ROCEReturn on capital employed | +8.2% | -145.7% | +9.7% | +14.2% | +30.5% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 4 | 6 | 7 | 6 |
| Debt / EquityFinancial leverage | 0.75x | 0.13x | 0.77x | 0.04x | — |
| Net DebtTotal debt minus cash | $23.7B | -$172M | $54.0B | -$1.0B | $1.7B |
| Cash & Equiv.Liquid assets | $9.5B | $194M | $24.4B | $1.1B | $5.7B |
| Total DebtShort + long-term debt | $33.2B | $22M | $78.4B | $70M | $7.4B |
| Interest CoverageEBIT ÷ Interest expense | 5.39x | -189.82x | 4.71x | 32.30x | 33.79x |
Total Returns (Dividends Reinvested)
MCK leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in MCK five years ago would be worth $38,689 today (with dividends reinvested), compared to $3,090 for DBVT. Over the past 12 months, DBVT leads with a +110.4% total return vs ELV's -9.0%. The 3-year compound annual growth rate (CAGR) favors MCK at 27.3% vs UNH's -7.1% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +5.8% | +4.9% | +10.6% | +25.3% | -8.5% |
| 1-Year ReturnPast 12 months | -9.0% | +110.4% | -3.2% | +16.5% | +4.6% |
| 3-Year ReturnCumulative with dividends | -15.6% | +19.7% | -19.9% | +14.5% | +106.4% |
| 5-Year ReturnCumulative with dividends | +1.5% | -69.1% | -2.6% | +60.9% | +286.9% |
| 10-Year ReturnCumulative with dividends | +202.1% | -87.0% | +220.6% | -11.0% | +348.1% |
| CAGR (3Y)Annualised 3-year return | -5.5% | +6.2% | -7.1% | +4.6% | +27.3% |
Risk & Volatility
Evenly matched — ALKS and MCK each lead in 1 of 2 comparable metrics.
Risk & Volatility
MCK is the less volatile stock with a 0.04 beta — it tends to amplify market swings less than DBVT's 1.26 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ALKS currently trades 96.7% from its 52-week high vs MCK's 75.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.46x | 1.26x | 0.59x | 1.06x | 0.04x |
| 52-Week HighHighest price in past year | $424.24 | $26.18 | $395.52 | $36.60 | $999.00 |
| 52-Week LowLowest price in past year | $273.71 | $7.53 | $234.60 | $25.17 | $637.00 |
| % of 52W HighCurrent price vs 52-week peak | +87.9% | +76.3% | +93.5% | +96.7% | +75.3% |
| RSI (14)Momentum oscillator 0–100 | 75.5 | 48.1 | 75.9 | 60.2 | 16.2 |
| Avg Volume (50D)Average daily shares traded | 1.9M | 252K | 7.9M | 2.3M | 757K |
Analyst Outlook
UNH leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: ELV as "Buy", DBVT as "Buy", UNH as "Buy", ALKS as "Buy", MCK as "Buy". Consensus price targets imply 131.8% upside for DBVT (target: $46) vs 2.5% for ELV (target: $382). For income investors, UNH offers the higher dividend yield at 2.35% vs MCK's 0.36%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $382.38 | $46.33 | $385.43 | $44.00 | $1006.50 |
| # AnalystsCovering analysts | 37 | 15 | 52 | 28 | 31 |
| Dividend YieldAnnual dividend ÷ price | +1.8% | — | +2.4% | — | +0.4% |
| Dividend StreakConsecutive years of raises | 15 | 0 | 25 | 0 | 17 |
| Dividend / ShareAnnual DPS | $6.89 | — | $8.70 | — | $2.69 |
| Buyback YieldShare repurchases ÷ mkt cap | +3.2% | 0.0% | +1.7% | +0.5% | +3.4% |
MCK leads in 2 of 6 categories (Profitability & Efficiency, Total Returns). ALKS leads in 1 (Income & Cash Flow). 2 tied.
ELV vs DBVT vs UNH vs ALKS vs MCK: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is ELV or DBVT or UNH or ALKS or MCK a better buy right now?
For growth investors, McKesson Corporation (MCK) is the stronger pick with 16.
2% revenue growth year-over-year, versus -5. 2% for Alkermes plc (ALKS). Elevance Health Inc. (ELV) offers the better valuation at 14. 8x trailing P/E (13. 9x forward), making it the more compelling value choice. Analysts rate Elevance Health Inc. (ELV) a "Buy" — based on 37 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — ELV or DBVT or UNH or ALKS or MCK?
On trailing P/E, Elevance Health Inc.
(ELV) is the cheapest at 14. 8x versus McKesson Corporation at 29. 2x. On forward P/E, Elevance Health Inc. is actually cheaper at 13. 9x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: McKesson Corporation wins at 0. 49x versus Elevance Health Inc. 's 2. 01x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.
03Which is the better long-term investment — ELV or DBVT or UNH or ALKS or MCK?
Over the past 5 years, McKesson Corporation (MCK) delivered a total return of +286.
9%, compared to -69. 1% for DBV Technologies S. A. (DBVT). Over 10 years, the gap is even starker: MCK returned +348. 1% versus DBVT's -87. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — ELV or DBVT or UNH or ALKS or MCK?
By beta (market sensitivity over 5 years), McKesson Corporation (MCK) is the lower-risk stock at 0.
04β versus DBV Technologies S. A. 's 1. 26β — meaning DBVT is approximately 2818% more volatile than MCK relative to the S&P 500. On balance sheet safety, Alkermes plc (ALKS) carries a lower debt/equity ratio of 4% versus 77% for UnitedHealth Group Incorporated — giving it more financial flexibility in a downturn.
05Which is growing faster — ELV or DBVT or UNH or ALKS or MCK?
By revenue growth (latest reported year), McKesson Corporation (MCK) is pulling ahead at 16.
2% versus -5. 2% for Alkermes plc (ALKS). On earnings-per-share growth, the picture is similar: McKesson Corporation grew EPS 14. 9% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Over a 3-year CAGR, UNH leads at 11. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — ELV or DBVT or UNH or ALKS or MCK?
Alkermes plc (ALKS) is the more profitable company, earning 16.
4% net margin versus 0. 0% for DBV Technologies S. A. — meaning it keeps 16. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ALKS leads at 17. 2% versus 0. 0% for DBVT. At the gross margin level — before operating expenses — ALKS leads at 86. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is ELV or DBVT or UNH or ALKS or MCK more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, McKesson Corporation (MCK) is the more undervalued stock at a PEG of 0. 49x versus Elevance Health Inc. 's 2. 01x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Elevance Health Inc. (ELV) trades at 13. 9x forward P/E versus 20. 2x for UnitedHealth Group Incorporated — 6. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for DBVT: 131. 8% to $46. 33.
08Which pays a better dividend — ELV or DBVT or UNH or ALKS or MCK?
In this comparison, UNH (2.
4% yield), ELV (1. 8% yield), MCK (0. 4% yield) pay a dividend. DBVT, ALKS do not pay a meaningful dividend and should not be held primarily for income.
09Is ELV or DBVT or UNH or ALKS or MCK better for a retirement portfolio?
For long-horizon retirement investors, Elevance Health Inc.
(ELV) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 46), 1. 8% yield, +202. 1% 10Y return). Both have compounded well over 10 years (ELV: +202. 1%, DBVT: -87. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between ELV and DBVT and UNH and ALKS and MCK?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: ELV is a mid-cap deep-value stock; DBVT is a mega-cap quality compounder stock; UNH is a large-cap quality compounder stock; ALKS is a small-cap quality compounder stock; MCK is a mid-cap high-growth stock. ELV, UNH pay a dividend while DBVT, ALKS, MCK do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.